Search for Clinical Trial Results
Nonseminomatous Germ Cell Tumor - 25 Studies Found
Status | Study |
Recruiting |
Study Name: A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors Condition: Non-seminomatous Germ-cell Tumors Date: 2014-04-10 Interventions: Drug: Cabazitaxel On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², |
Active, not recruiting |
Study Name: Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours Condition: Stage I Testicular Non-Seminomatous Germ Cell Tumor Date: 2012-11-09 Interventions: Drug: BEP(500) One cycle of BEP(500): |
Active, not recruiting |
Study Name: Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors Condition: Germ Cell Tumor Date: 2005-08-03 Interventions: Drug: gemcitabine, ifosfamide, cisplatin, G-CSF |
Recruiting |
Study Name: Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy Condition:
Date: 2014-08-25 Interventions:
|
Recruiting |
Study Name: Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Condition:
|
Completed |
Study Name: Positron Emission Tomography in Detecting Testicle Cancer Condition: Testicular Germ Cell Tumor Date: 2002-09-06 Interventions:
|
Completed |
Study Name: Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer Condition: Testicular Germ Cell Tumor Date: 2007-11-02 Interventions:
|
Completed |
Study Name: Diagnostic Study of Patients With Stage I Testicular Cancer Condition: Testicular Germ Cell Tumor Date: 1999-11-01 Interventions:
|
Recruiting |
Study Name: First Line TIP in Poor Prognosis TGCTs. Condition: Germ Cell Tumor Date: 2015-04-08 Interventions:
|
Recruiting |
Study Name: Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Condition:
Interventions: Drug: Brentuximab Vedotin Both cohorts will be treated similarly and in parallel but analyzed separately |